GLP-1 medications and sleep apnoea
Direct answer
What you need to know
Evidence strength: StrongOne GLP-1 medication is FDA-approved for obstructive sleep apnoea. Zepbound (tirzepatide) carries an approved indication for OSA in adults with obesity, alongside its weight-management approval. That is a stronger thing than a marketing claim or a promising study — it means a regulator reviewed the evidence and agreed. It is not a reason to stop using CPAP, and no other product in the class carries this approval.
Key takeaways
- Zepbound is approved for obstructive sleep apnoea in adults with obesity.
- No other GLP-1 medication carries an OSA indication.
- An approval is not a promise about your own apnoea, or a discharge from your sleep clinic.
- Never stop CPAP on the strength of a medication starting — that is a clinician's call.
Important limitation: This page states approval status, which we can verify, and deliberately publishes no effect sizes from the trial programme. It also says nothing about central sleep apnoea, about people without obesity, or about children.
Next action: If you have diagnosed OSA and are considering a GLP-1, this is a conversation for both teams — the one managing your apnoea and the one prescribing. Ask about re-testing rather than assuming improvement.
Primary sources: DailyMed, U.S. National Library of Medicine, U.S. Food & Drug Administration, ClinicalTrials.gov, U.S. National Library of Medicine
General education, not medical advice. Do not change or stop any sleep-apnoea treatment based on this page.
Why an approval is the part that matters
Almost everything written about GLP-1 medications and sleep apnoea is downstream of weight loss: lose weight, breathe better. That reasoning is not wrong, but it is the kind of claim anyone can make about anything that reduces weight.
What is different here is narrower and more checkable. Zepbound (tirzepatide) was studied specifically in obstructive sleep apnoea, under the SURMOUNT-OSA programme, and now carries an approved indication for it in adults with obesity. A regulator looked at the data and agreed the drug does this. That is a materially stronger position than “may help”.
The useful question is not whether a GLP-1 might improve your apnoea. It is whether the specific product you are being offered is the one that was actually tested for it.
What we are not publishing, and why
You will find pages quoting a precise reduction in apnoea-hypopnoea index from the trial programme. We are not going to, because we cannot currently verify those figures against the primary publication to the standard the rest of this site is held to. Approval status we can verify; effect sizes we cannot, today.
That gap is stated rather than filled, the same way the deliberate omissions are handled on our statistics page. If a number matters to your decision, it should come from the trial publication or your clinician, not from us repeating it second-hand.
Which product, and what that means practically
| Product | Molecule | Approved for |
|---|---|---|
| Zepbound | Tirzepatide | Chronic weight management; obstructive sleep apnoea in adults with obesity |
| Every other GLP-1 | — | No obstructive sleep apnoea indication |
Two practical consequences. First, if OSA is the reason you want the medication, the product matters — and a prescriber can only write for the indication that exists. Second, an approved indication can change what an insurer will cover, which is often the decisive factor: see cost and coverage.
Do not treat this as permission to stop CPAP
- An approval for a population is not a prediction about you. Apnoea severity is measured, not assumed, and only a repeat sleep study can tell you whether yours has changed.
- Stopping CPAP prematurely returns you to untreated apnoea, with the daytime sleepiness and cardiovascular risk that carries. That decision belongs to the team managing your apnoea.
- Tell your sleep team that you are starting a GLP-1. It is relevant to them even if nobody thought to ask.
- This page is about obstructive sleep apnoea. Central sleep apnoea is a different condition and nothing here applies to it.
Sources
Each source below supports specific statements on this page. We cite the strongest available authority and verify against the current version before publishing.
- FDA-approved prescribing information (drug labels)DailyMed, U.S. National Library of MedicineSupports: The approved indications for Zepbound, including obstructive sleep apnoea in adults with obesity — the basis for every statement of approval status on this page.
- Drug approvals, labeling and safety communicationsU.S. Food & Drug AdministrationSupports: Approval status and approved indication, checkable in Drugs@FDA and the Orange Book.
- Clinical trial registry and resultsClinicalTrials.gov, U.S. National Library of MedicineSupports: The SURMOUNT-OSA trial programme, under which tirzepatide was studied in obstructive sleep apnoea.
This page is general education, not medical advice. Talk to your own healthcare provider about your situation before starting, stopping, or changing any medication.